Background and Purpose-Although rivaroxaban 15 mg (R15) was only given to patients with creatinine clearance (CrCl) ≤50 mL/min in the pivotal clinical trial, this dose has been commonly prescribed in Asian patients with nonvalvular atrial fibrillation regardless of renal function. There is a paucity of information on the clinical outcomes of R15 compared with rivaroxaban 20 mg (R20) in patients with CrCl ≥50 mL/min. This study aimed to examine the effectiveness and safety of 2 doses of rivaroxaban in Asian patients with atrial fibrillation and CrCl ≥50 mL/min. Methods-Using the Korean National Health Insurance Service database, patients with atrial fibrillation and normal or mildly impaired renal function (CrCl ≥50 mL/min) and naive to rivaroxaban or warfarin were included from January 2014 to December 2016. Three separate 1:1 propensity score-matched cohorts were conducted: R20 versus warfarin (n=15 584), R15 versus warfarin (n=11 554), and R20 versus R15 (n=10 392). Hazard ratios for ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause death, and composite clinical outcome were analyzed. Results-Compared with warfarin, both R20 and R15 showed significantly lower risk for ischemic stroke, major bleeding (mainly through reduction of intracranial hemorrhage), and all-cause death. Compared with R15, R20 showed better results for the composite clinical outcome (hazard ratio, 0.852; 95% CI, 0.735-0.988). This benefit was consistently observed in patients aged ≥80 years and those <50 kg. R20 was associated with higher risk of major bleeding than R15 in patients with marginal CrCl (50-60 mL/min). Conclusions-Among Asians with atrial fibrillation and CrCl ≥50 mL/min, both R20 and R15 were associated with reduced risk of ischemic stroke, intracranial hemorrhage, major bleeding, and all-cause death without significantly increased risk of gastrointestinal bleeding compared with warfarin. In patients with CrCl ≥50 mL/min, on-label R20 showed better results for the composite clinical outcome compared with off-label R15.
T he prevalence and incidence of atrial fibrillation (AF) is rapidly increasing, especially in Asian countries, resulting in an increased healthcare burden. 1 Oral anticoagulation (OAC) is the mainstay for stroke prevention in patients with AF, but anticoagulation therapy is generally underutilized in Asian countries. 2, 3 Recently, non-vitamin K antagonist oral anticoagulants (NOACs) have been introduced, with similar or better efficacy and safety compared with warfarin in nonvalvular AF patients, thus leading to increased prescribing in Asians. [2] [3] [4] Rivaroxaban showed comparable efficacy for stroke prevention and less frequent intracranial hemorrhage (ICH) than warfarin in the ROCKET-AF trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 5 In ROCKET-AF, on-label dosing of rivaroxaban was 20 mg once daily with lowering to 15 mg once daily for patients with moderate renal impairment (creatinine clearance [CrCl] 30 to 49 mL/min) based on pharmacokinetic data. 6, 7 In real-world practice, especially among Asians, reduced-dose rivaroxaban has been prescribed more commonly irrespective of renal function. [8] [9] [10] [11] [12] However, there are concerns about the use of rivaroxaban 15 mg (R15) in patients with normal renal function or mild renal impairment (CrCl ≥50 mL/min). Considering the decreased effectiveness for stroke prevention without benefit of safety for off-label underdosing, 13, 14 the optimal dose of rivaroxaban for Asian AF patients with normal or mildly impaired renal function is still controversial.
In the present study, we aimed to examine the effectiveness, safety, and composite clinical outcome of the 2 doses of rivaroxaban (20 mg and 15 mg) in a real-world setting with Asian AF patients with CrCl ≥50 mL/min. First, we evaluated the effectiveness and safety of rivaroxaban 20 mg (R20; on label) and 15 mg (off label) compared with warfarin. Second, a comparison of (on label) R20 with (off label) R15 was conducted.
Methods Database
This study was conducted using an observational, retrospective, nationwide cohort derived from administrative claims data of the Korean National Health Insurance Service and the linked health checkup database of the National Health Insurance Corporation. The Korean National Health Insurance Service provides comprehensive medical care coverage for the entire Korean population (≈50 million people) and includes individual demographic information, diagnoses, and prescription and procedure records for inpatient and outpatient medical use, as reported elsewhere. 1, 3, 9, [15] [16] [17] This study was exempted from review by the Seoul National University Hospital Institutional Review Board (E-1805-006-941). All data have been made publicly available at National Health Insurance Data Sharing Service (accessed at http://nhiss.nhis.or.kr/ bd/ab/bada000eng.do).
Study Design
We identified 263 263 adult patients who had ≥1 pharmacy claim for OACs during identification period (from January 1, 2013 to December 31, 2016) and excluded the patients who had a pharmacy claim for any OAC before January 1, 2014. Thus, we included patients naive to OAC treatment between January 2014 and December 2016. We excluded patients who had alternative indications for OAC treatment, such as valvular AF, deep vein thrombosis, pulmonary embolism, or joint replacement surgery. We also excluded patients with end-stage renal disease. In the Korean National Health Insurance Service, repeated clinical outcomes do not differentiate between new-onset clinical events and the incidence could be overestimated; hence, patients with prior ischemic stroke, ICH, or gastrointestinal bleeding were excluded for accurate assessment of clinical outcomes. 9, 16 Of 58 838 eligible patients with CrCl information within 2 years before index OAC initiation, those on rivaroxaban (20 mg or 15 mg) or warfarin were identified. Of these, patients with moderate renal impairment (CrCl <50 mL/min) were excluded. Finally, 3 sets of matched cohorts were analyzed: R20 (on-label) versus warfarin (7792 patients each); R15 (off-label) versus warfarin (5777 patients each); and R20 (on-label) versus 15 mg (off-label, 5196 patients each, Figure 1 ).
Covariates and Comorbidities
Baseline characteristics including age, sex, and comorbidities were evaluated. Prevalent hypertension, diabetes mellitus, dyslipidemia, congestive heart failure, peripheral artery disease, chronic obstructive pulmonary disease, and prior myocardial infarction were defined using diagnosis codes in the International Classification of Disease, Tenth Revision, Clinical Modification, based on prescription records and inpatient/outpatient hospital visits within 1 year before the index date ( Table I in the online-only Data Supplement). The CHA 2 DS 2 -VASc score was calculated by assigning 1 point each for congestive heart failure, hypertension, diabetes mellitus, vascular disease (prevalent peripheral artery disease or prior myocardial infarction), age 65 to 74 years, female sex, and 2 points each for age ≥75 years and prior stroke/transient ischemic attack/systemic thromboembolism. 18 CrCl calculated using the Cockcroft-Gault method, body weight, and body mass index were also analyzed.
Study Outcomes and Follow-Up
To assess effectiveness and safety, 6 clinical outcomes, including ischemic stroke, ICH, hospitalization for gastrointestinal bleeding, hospitalization for major bleeding (ICH±hospitalization for gastrointestinal bleeding), all-cause death, and the composite clinical outcome (ischemic stroke±hospitalization for major bleeding [ICH±hospitalization for gastrointestinal bleeding]±all-cause death) as a measure of net clinical outcome, 16 were identified during follow-up. Detailed definitions of clinical outcomes are described in Table I in the online-only Data Supplement. Patients were followed up by the end of study period (December 31, 2016). Patients were censored at firstly occurred each predefined clinical outcome. For composite clinical outcome, the event time was defined as the time to first occurrence among components of composite clinical outcome.
Statistical Analysis
For the comparison of R20 versus warfarin, R15 versus warfarin, and R20 versus R15, 3 separate pairs of 1:1 propensity score-matched cohorts were constructed. 16, 19, 20 For matching, the propensity for being in a specific treatment group was calculated using a logistic regression model with all baseline covariates as follows: age, sex, CHA 2 DS 2 -VASc score, hypertension, diabetes mellitus, dyslipidemia, 
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congestive heart failure, previous myocardial infarction, peripheral artery disease, chronic obstructive pulmonary disease, renal function assessed by CrCl, and body weight. Separate propensity score models were obtained for the R20-warfarin, R15-warfarin, and R20-R15 comparisons. In 3 cohorts (R20 versus warfarin, R15 versus warfarin, and R20 versus R15), patients were matched in a 1:1 manner between 2 treatment groups using the greedy, nearest-neighbor method without replacement with a caliper of 0.01 of the propensity score. 19 To confirm balance between the 2 treatment groups, the absolute standardized difference (ASD) was used. An ASD of ≤0.1 (10%) was an acceptable difference between the 2 treatment groups for each covariate. 21 When the ASD was >0.1, the covariate was adjusted in the Cox proportional hazards regression model.
For the 6 clinical outcomes, incidence rates were assessed using the total number of clinical events during the follow-up period divided by 100 person-years at risk. The risks of clinical outcomes over time for R20 or R15 compared with warfarin (reference) were analyzed using survival analysis. Hazard ratios (HRs) and 95% CIs were analyzed using Cox proportional hazards regression models. KaplanMeier analyses with log-rank tests were also performed. For comparison of R20 versus R15, HRs of 6 clinical outcomes were evaluated with R15 as the reference.
Statistical significance was defined as P<0.05. All statistical analyses were performed using SAS 9.3 (SAS Institute, Inc, Cary, NC).
Sensitivity Analysis
Although both warfarin and rivaroxaban were available during whole study period in Korea, NOAC use, including rivaroxaban, rapidly increased after July 2015 when NOAC was more widely approved in nonvalvular AF patients by reimbursement policy. Thus, we conducted a sensitivity analysis restricting the follow-up duration to 6-month to balance the follow-up period between warfarin and rivaroxaban groups. 16 
Subgroup Analyses
In a comparison between R20 and R15, subgroup analyses were performed based on age (<80 years old or ≥80 years old), 22 body weight (<50 kg or ≥50 kg), 23 and renal function (CrCl, 50-60 or ≥60 mL/ min). 24 We also analyzed 4 subgroups of patients according to renal function: ≥50 to 60 mL/min, >60 to 80 mL/min, >80 to 95 mL/min, and ≥95 mL/min. 25 For each subgroup, balance between baseline covariates was evaluated, and the covariate was adjusted in the Cox proportional hazards model when the ASD was >10%. The statistical significance of the interaction between treatment and specific subgroups was defined as P for interaction <0.1.
Results
We included 20 431 patients taking warfarin, 7798 patients taking on-label R20, and 5796 patients taking off-label R15, with median follow-up of 1.4 years (interquartile range, 0.8-2.5 years; Figure 1 ). Among the pooled total study population, mean age was 66.9±10.9 years, 62.2% were male, mean CHA 2 DS 2 -VASc score was 3.16±1.79, and mean CrCl was 83.6±42.0 mL/min (median, 78.4 mL/min; interquartile range, 67.7-91.0 mL/min).
Effectiveness and Safety of R20 and R15 Compared With Warfarin in Patients With CrCl ≥50 mL/min
Before propensity score matching, both R20 and R15 groups were older, with higher CH 2 DS 2 -VASc scores and higher prevalence of comorbidities including hypertension, diabetes mellitus, dyslipidemia, and peripheral artery disease, compared with the warfarin group (Table II in the online-only Data Supplement). After propensity score matching, each R20-warfarin and R15-warfarin group was well balanced for all covariates (all ASD <0.1; Table 1 and Figure I in the online-only Data Supplement).
The incidence rates and cumulative incidence curves for the 6 clinical outcomes are presented in Table 2 and Figures II and III in the online-only Data Supplement. Both R20 and R15 were associated with significantly lower risk of ischemic stroke, major bleeding (mainly through reduction of ICH), and all-cause death compared with warfarin (Figure 2A and 2B). R20 showed a nonsignificant trend toward a reduced risk of hospitalization for gastrointestinal bleeding compared with warfarin, whereas R15 was not significantly different. Overall, both R20 and R15 had better results for the composite clinical outcome compared with warfarin (HR, 0.617; 95% CI, 0.550-0.691 for R20 and HR, 0.759; 95% CI, 0.675-0.853 for R15).
Comparison Between On-Label R20 and Off-Label R15 for 6 Clinical Outcomes in Patients With CrCl ≥50 mL/min Before propensity score matching, the R15 group was older and had more women compared with the R20 group; the R15 group had higher CHA 2 DS 2 -VASc scores and smaller body size compared with the R20 group (Table II in the onlineonly Data Supplement). After propensity score matching, the R20 and R15 groups were well balanced for all covariates (all ASD <0.1; Table 1 and Figure I in the online-only Data Supplement).
The incidence rates and cumulative incidence curves for the 6 clinical outcomes are presented in Table 2 and Figure  IV in the online-only Data Supplement. Compared with off-label R15, on-label R20 showed a nonsignificant trend toward lower risks of ischemic stroke, hospitalization for gastrointestinal bleeding, hospitalization for major bleeding, and all-cause death ( Figure 2C ). No significant difference was found in ICH risk for R20 versus R15. Off-label R15 did not significantly reduce the risk of ICH, gastrointestinal bleeding, and major bleeding. Overall, on-label R20 had better results for the composite clinical outcome compared with off-label R15 in patients with CrCl ≥50 mL/min (HR, 0.852; 95% CI, 0.735-0.988; Figure 2C ).
Sensitivity Analysis
The median follow-up varied between treatment groups: 2.22 (interquartile range, 1.32-3.07) years for warfarin groups, 1.01 (0.56-1.34) years for R20 group, and 0.84 (interquartile range, 0.43-1.22) years for R15 group. A sensitivity analysis was performed to balance for the differences in the follow-up duration among 3 groups. HR trends for all 6 clinical outcomes were similar to the 6-month follow-up results across all 3 comparison cohorts (Table III in 
Subgroup Analyses
Age (<80 Years, ≥80 Years) No significant interaction was found between treatment (R20 versus R15) and age for all clinical outcomes except for allcause death ( Figure 3 and Table IV in the online-only Data Supplement). In the very elderly (≥80 years), R20 was not associated with a significant increase in bleeding outcomes, including ICH, gastrointestinal bleeding, and major bleeding.
Body Weight (<50 kg, ≥50 kg) There was no significant interaction with body weight in regard to all 6 clinical outcomes ( Figure 3 and Table IV in the online-only Data Supplement). In patients with extremely low body weight (<50 kg), R20 use was not related to higher bleeding risk compared with R15.
Renal Function (50 mL/min ≤ CrCl ≤60 mL/min, CrCl >60 mL/min) There was no significant interaction for ischemic stroke and all-cause death between treatment and renal function, but a significant interaction for ICH, major bleeding, and the composite clinical outcome was found ( Figure 3 and Table IV in the online-only Data Supplement). In patients with CrCl 50 to 60 mL/min, R20 showed a nonsignificant trend toward higher risk of ICH (HR, 3.323; 95% CI, 0.962-15.32), major bleeding (HR, 1.828; 95% CI, 0.994-3.452), and the composite clinical outcome (HR, 1.153; 95% CI, 0.789-1.688) compared with R15.
Risk of Major Bleeding for R20 Versus R15 Stratified by Renal Function in the Total Cohort
In patients with CrCl 50 to 60 mL/min, R20 showed a nonsignificant trend toward a higher risk of hospitalization for major bleeding compared with R15 (HR, 1.828; 95% CI, 0.994-3.452; Figure 4 ). R20 did not increase major bleeding risk in patients with CrCl >60 to 80, >80 to 95, and ≥95 mL/min. For hospitalization for major bleeding, the risk of R20 compared with R15 showed significant interaction among CrCl subgroups (P for interaction=0.036). Otherwise, no significant interactions were found between treatment and renal function with regard to the remaining 5 clinical outcomes (Tables V and VI in the online-only Data Supplement).
Discussion
To the best of our knowledge, this is the first real-world population-based study to investigate the effectiveness and safety of rivaroxaban in normal or mildly impaired renal function comparing both 20 mg and 15 mg in Asian patients with AF. No study has previously compared the composite clinical outcome of R20 versus R15 in patients with CrCl ≥50 mL/min in well-matched population-based cohorts. Our study shows the following (1) a substantial proportion (42.6%) of patients with CrCl ≥50 mL/min were prescribed off-label R15 for stroke prevention in the Korean AF population; (2) compared with warfarin, both on-label R20 and off-label R15 were associated with better outcomes for ischemic stroke, major bleeding, all-cause death, and the composite clinical outcome; (3) R20 showed better results for the composite clinical outcome compared with R15 in patients with normal or mildly impaired renal function; and (4) in patients with marginal CrCl (50-60 mL/min), on-label R20 showed a higher risk of major bleeding compared with off-label R15. In ROCKET-AF, rivaroxaban was noninferior to warfarin for prevention of thromboembolic events (HR, 0.88; 95% CI, 0.74-1.03) and showed similar risk of major bleeding but significant reduction of ICH compared with warfarin in AF patients at relatively high stroke risk. 5 However, the ROCKET AF population only included 6.5% who were Asian. Considering the significant interaction of NOACs' benefit between non-Asians and Asians, there has been a need to demonstrate the effectiveness and safety of rivaroxaban in large-scale Asian populations. [26] [27] [28] The J-ROCKET AF trial (Rivaroxaban vs Warfarin in Japanese Patients With Atrial Fibrillation) reported the efficacy and safety of R15 (dose reduction to 10 mg rivaroxaban in patients with CrCl 30 to 49 mL/min) based on pharmacodynamic data in Japanese AF patients. 11 Compared with warfarin, R15 was associated with a better outcome in stroke and systemic embolism but only showed borderline statistical significance (P=0.05) and was underpowered owing to small sample size. Moreover, as the number of participating patients was small (n=637), this result cannot be generalized to the whole Asian population.
Although stroke prevention has generally improved among Asians, OAC treatment is commonly underutilized in this region. 3 Fear of bleeding events, poor international normalized ratio control owing to diet, inconvenience of having to monitor anticoagulation, prescription of antiplatelet agents, and low adherence have all been linked to less prescribing of OACs, thus increasing the risk of stroke in Asian patients with AF. 28 In several previous reports, R15 in patients with normal or mildly impaired renal function was defined as off-label underdosing, and off-label underdosing showed a worse outcome in stroke prevention without benefit for bleeding complications. 13, 14, 29 Therefore, further studies are required about the efficacy and safety of rivaroxaban compared with warfarin and the optimal dose of rivaroxaban for Asian patients with AF.
In this study, we demonstrated that both on-label R20 and off-label R15 were associated with lower risk of ischemic stroke, major bleeding, and all-cause death compared with warfarin in patients with normal or mildly impaired renal function. These results are largely consistent with the Asian subgroup analyses of pivotal trials and recently published Asian real-world evidence. 8, 26, 27, 30, 31 Regardless of renal function, almost 90% of patients received reduced-dose rivaroxaban (15 or 10 mg) in a Taiwanese nationwide cohort. 8, 30 The present study includes the largest number of patients taking R20 in an Asian population and is, therefore, the first study to show the comparative effectiveness and safety of on-label R20 compared with warfarin in the Asian population.
Off-label dose prescribing of NOACs is common in realworld clinical practice. Several studies attempted to address the clinical impact of off-label dosing of NOACs.
13,14,29 There is general consensus that off-label dosing may be associated with an increased risk of stroke, with no benefit for the reduction of bleeding complications. Nevertheless, demonstrating the hazard of off-label underdosing of NOACs is challenging, given that the differences are likely to be modest. Looking into the detailed results of previous studies, off-label dosing showed unfavorable trends for outcomes, but the findings were not statistically significant. 14, 29 A recent study from Taiwan suggested that low dose (15 or 10 mg) rivaroxaban might be associated with worse clinical outcomes not only for ischemic stroke but also for bleeding outcomes. 31 However, patient clinical profiles were not matched among the different dosing groups of rivaroxaban, leading to bias in interpreting the results; moreover, data were analyzed regardless of renal function. Generally, patients who received reduced doses of NOACs tended to be frail and were at higher risk of thromboembolism and bleeding. In our study, before propensity score matching, the R15 group was older and had higher CHA 2 DS 2 -VASc scores and lower body weight than the R20 group. After careful matching, R20 showed better results for the composite clinical outcome compared with R15 in patients with normal or mildly impaired renal function. This is consistent with previous studies and offers insight into the best risk-to-benefit balance for rivaroxaban dosing. 13, 14, 29 Although dose reduction of rivaroxaban (20 to 15 mg) is only recommended in patients with moderate renal impairment (CrCl, 30-49 mL/min), physicians widely prescribe R15 in patients with CrCl ≥50 mL/min, especially in Asians. 9, 10, 31 Physicians tend to prescribe the reduced dose for patients with older age and low body weight owing to misperception in dose reduction criteria. In our study, the very elderly (≥80 years) and those with low body weight (<50 kg) did not show significant interactions with dose regimens. In other words, the clinical benefit of on-label R20 was consistent in very elderly patients and those with low body weight. These results are consistent with the pharmacokinetic data on rivaroxaban. 6, 7, 32, 33 Although CrCl is the only factor that can affect rivaroxaban concentration according to pharmacokinetics data, whether a CrCl of 50 mL/min is the most optimal cutoff for dose reduction in Asian patients is unclear. According to results of present study, there was a signal indicating that R20 might have a higher risk of hospitalization for major bleeding compared with R15 in patients with CrCl 50 to 60 mL/min; however, owing to small numbers of patients, statistical significance was not observed. In addition, in our study, the database only obtained baseline CrCl, and therefore, fluctuation or decline of renal function could not be evaluated. Further investigation is needed to define the optimal CrCl cutoff for dose reduction in the Asian population. Furthermore, careful evaluation and follow-up of renal function and immediate dose adjustment is also needed at the patient-care level.
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Study Limitations
First, given the inherent limitation of administrative claims data, diagnoses were defined by diagnostic codes, and drug prescription was identified by claims database. Possibility of lack of clinical accuracy or coding errors might cause bias in the study. In addition, although we matched and assessed the balance between 2 treatment groups in each cohort using propensity scoring, unmeasurable residual confounding factors may have remained. It is not possible to fully identify rationale for treatment decisions, and this biased allocation results limited claims of causality. Indeed, only associations rather than causal relationships could be concluded from this retrospective observational study. Nevertheless, in the absence of head-to-head clinical trial for such comparisons conducted in this study, our results based on nationwide observational cohort can provide complementary value to clinical trials especially in clinical practice. Second, the quality of warfarin treatment could not be evaluated owing to the absence of time in therapeutic range information. Third, we included nonvalvular AF patients who initiated OAC during study period from entire Korean population. To compare the effectiveness and safety of warfarin, R20 and R15 in patients with CrCl ≥50 mL/min, we only included patients with CrCl information among OAC naive patients with nonvalvular AF. Patients who had CrCl information indicated patients who received the national health checkup provided by government, and there might be possibility of selection bias. Patients without CrCl information was older, more likely to be female, had more prevalent comorbidities and had higher CHA 2 DS 2 -VASc score than those with CrCl information (Table VII in the online-only Data Supplement). These data should be interpreted and applied cautiously to the general population. Fourth, we excluded patients with alternative indications for OAC treatment to define study patients who received OAC for stroke prevention in nonvalvular AF. Also, we excluded patients with prior ischemic stroke, ICH, and gastrointestinal bleeding for accurate assessment of clinical outcomes. 9, 16 Further study is needed for these multimorbid and high-risk patients. Fifth, although propensity score matching is useful and widely used method to balance 2 treatment groups, some patients are unmatched leading to information excluded from the analysis. Therefore, we also performed inverse probability weighting method. After propensity score weighting, all covariates were well balanced between R15 and R20 (Table VIII in the online-only Data Supplement). Both the results from propensity score matching and inverse probability weighting method were consistent (Figure V and Table  IX in the online-only Data Supplement). Sixth, actual drug adherence could not be measured because of the inherent limitations of claims data. Seventh, change in renal function over time was not recorded. There is a possibility that CrCl fluctuation or decline could occur in patients with marginal renal function, which might affect clinical outcomes. Lastly, this study was conducted from the claims database of the Korean population. Therefore, the ethnic uniformity of this cohort should be considered when generalizing these results to other Asian populations.
Although the proportion of patients treated with rivaroxaban among AF patients who needed OAC treatment might vary across different countries, rivaroxaban users represented the largest proportion among NOAC-users in OAC naive patients with AF (ie, 42% of NOAC-users, followed by 27% using dabigatran, then 23% apixaban, and 8% edoxaban) during the study period. To evaluate more recent status, when extending the database to December 31, 2017, rivaroxaban still represented 40% of NOAC-users. Thus, the proportion of patients treated with rivaroxaban was high among Korean patients with nonvalvular AF. According to the previous study based on Taiwanese national insurance data, the proportion of patients treated with rivaroxaban was the largest (52%) among patients treated with NOACs. 30 Therefore, this topic is an important issue in relation to defining the effectiveness and safety of rivaroxaban compared with warfarin and the optimal dose of rivaroxaban for Asian patients.
Conclusions
In real-world practice among Asian AF patients with CrCl ≥50 mL/min, both R20 and R15 were associated with reduced risk of ischemic stroke, ICH, major bleeding, and all-cause death, without a significant increase of hospitalization for gastrointestinal bleeding, compared with warfarin. However, in comparing the 2 dose regimens, on-label R20 showed better results for the composite clinical outcome compared with off-label R15. Further investigation is needed to find optimal CrCl cutoff value for dose reduction in the Asian population.
Sources of Funding
This study was supported by a Korea National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2014R1A1A2A16055218).
